Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments

Journal of Clinical Pharmacy and Therapeutics, EarlyView.

Source: Journal of Clinical Pharmacy and Therapeutics - June 16, 2018 Category: Drugs & Pharmacology Authors: T. Hirai PhD , R. Yamaga BSc , A. Fujita MS , T. Itoh MS Source Type: research